First! Well-known medical enterprises Bekang Medical is about to go public

market sources said that Beikang Medical had passed the listing hearing and planned to raise up to US$250 million (about HK$1.95 billion). According to the prospectus, Beikang Medical is a unicorn company with an assisted reproductive gene testing solution in China and the first company in China to have a high-volume gene sequencing (NGS) product line covering the entire reproductive cycle.Public information shows that Beckon Medical's PGT-A kit can screen embryos for normal development before implantation (a chromosomal disease often associated with failed IVF implants), the first and first high-volume gene sequencing kit approved by the State Drug Administration, marking the birth of China's PGT third-generation IVF "certificated" industrial genetic testing market.
In addition, Becon Medical is registering PGT-M and PGT-SR kits and is expected to receive a registration certificate from the National Drug Administration in 2022 and 2024, respectively. At that time, the two products will be together with the PGT-A kit to form a comprehensive coverage of the three-generation test tube gene testing needs of the kit series. These products are based on the latest high-volume gene sequencing technology, which will further strengthen Becon Medical's position as the only leader in the three-generation IVF genetic testing market.In 2019, one in six couples in China will face fertility difficulties, more than double the total number of assisted reproductive cycles (800,000 cycles) in the United States, according to the Health and Wellness Commission, and is undoubtedly the world's largest assisted reproductive market. However, the average pregnancy success rate of IVF in China is less than 50%, the average abortion rate is 33%, the average infertility couples need to go through 2.5 failures, 2 years of repeated cultivation to successfully have a child. Clinically the biggest pain point is that only through "form" to determine the good or bad embryo, before the embryo implanted into the human body can not accurately confirm whether the embryo is healthy and normal.The genetic testing product developed by Becon Medical is designed to address this clinical pain point and really help patients "live" and "eugenics" a healthy child by accurately screening each embryo at the full genetic level. After 4 years of the world's largest clinical trial test, the product can improve the success rate of IVF to 72%, abortion rate to 6.9%, has a very significant clinical significance and value, not only to fill china's three generations of IVF genetic testing technology gaps, but also to create a new track of assisted reproductive gene testing.In the field of reproductive health, the PGT product registration certificate is the second "big" certificate of NGS gene testing technology after the NIPT registration certificate. Listed companies engaged in NGS gene testing technology, such as Huada Gene, Berry and Kang, early success with the NIPT industry brought good into the rapid development period, Huada Gene after the listing valuation of up to 100 billion, Berry and Kang shell after the listing valuation of 10 billion. In addition, Jinxin Reproductive Medicine, which is listed in Hong Kong as the "first stock of assisted reproduction", has developed well in its assisted reproductive business since the completion of the global offering, with a total market value of $33 billion, which has also raised the focus of the HKEx on assisted reproduction. Becon Healthcare is expected to become the first NGS genetic testing unit on the Hong Kong Stock Exchange, and the company has also been well received by investors.It is reported that Beikang Medical had four rounds of financing before the listing, in July last year through the D-round financing, the introduction of High Capital and OrbiMed shares, gaoxuan currently holds 6.82 percent of the company's shares. This IPO CITIC Lyons as its sole sponsor, KPMG as its auditor, Tianyuan, Shengde as its company's Chinese lawyer, the company's Hong Kong lawyer, Tsushwe, Ruisheng as its brokerage China lawyer, brokerage Hong Kong lawyer, Frost Sullivan as its industry consultant.
(Cypress Blue)